REVERSIBLE BILATERAL SUBFOVEAL ELLIPSOID ZONE FOCAL THICKENING ASSOCIATED WITH OVERDOSE OF PHOSPHODIESTERASE TYPE 5 INHIBITORS INTAKE.

Purpose: To describe the clinical findings and outcome of an unusual case of subfoveal yellowish deposits associated with excessive doses of phosphodiesterase Type 5 inhibitors intake.

Methods: Single retrospective case report.

Results: A 50-year-old South American man with a personal history of multiple orally administered phosphodiesterase Type 5 inhibitors drugs to treat a chronic erectile dysfunction complained of dyschromatopsia, photophobia, and a 3-month history of blurred vision. The fundus examination revealed a symmetrical yellowish lesion in both eyes with a subfoveal hyperreflective signal on the spectral domain optical coherence tomography at the level of the ellipsoid zone. Dysregulation of the blue-yellow axis was noticed in the color vision test and the electroretinogram demonstrated a tiny decrease in the b-wave amplitude. The use of phosphodiesterase Type 5 inhibitors was discontinued and the patient was examined 3 months later. Optical coherence tomography revealed complete disappearance of the deposit in both eyes and the associated symptoms resolved rapidly with discontinuation of the drug.

Conclusion: A bilateral ellipsoid zone subfoveal focal thickening may be related to a yellowish symmetrical spot on the fovea in patients with a history of phosphodiesterase Type 5 inhibitors overdose intake. Functional and structural findings are reversible in a short-term period after discontinuing the oral treatment.